HBQ.F · Hofseth BioCare ASA

-

Please sign in to comment on HBQ.F

1 Comment

Admin

4 years, 1 month ago

Hofseth BioCare ASA is currently in a long term downtrend where the price is trading 5.2% below its 200 day moving average.

From a valuation standpoint, the stock is 96.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 41.6.

Hofseth BioCare ASA's total revenue rose by 106.9% to $23M since the same quarter in the previous year.

Its net income has increased by 7.1% to $-31M since the same quarter in the previous year.

Finally, its free cash flow fell by 3.2% to $-24M since the same quarter in the previous year.

Based on the above factors, Hofseth BioCare ASA gets an overall score of 3/5.

CurrencyCode	EUR
Sector	Healthcare
Industry	Biotechnology
Exchange	F
ISIN	NO0010598683

Beta	0.57
Market Cap	73M
PE Ratio	None
Target Price	None
Dividend Yield	None

ABOUT

Hofseth BioCare ASA

Hofseth BioCare ASA engages in the production of health nutritional products for humans and pets in Norway, the United Kingdom, France, Belgium, Italy, Germany, Europe, Japan, Asia, and the United States. The company's products include OmeGo, a salmon oil, which offers the full spectrum of fatty acids and omegas found naturally in fresh whole salmon; ProGo, a bioactive peptide for weight management, and metabolism; CalGo, a calcium collagen complex for bone and joint health; CollaGo; and PetGo, a non-soluble protein. The company was founded in 2000 and is headquartered in Ålesund, Norway.

HBQ.F · Hofseth BioCare ASA

-

Hofseth BioCare ASA

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Hofseth BioCare ASA using a moving average strategy